Absci Corp. ( (ABSI) ) has released its Q2 earnings. Here is a breakdown of the information Absci Corp. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Absci Corporation is a clinical-stage biopharmaceutical company that leverages generative AI to advance breakthrough therapeutics, primarily focusing on drug discovery and development in the biotechnology sector.
In its latest earnings report, Absci Corporation highlighted significant financial and operational milestones, including a strengthened balance sheet and expanded collaborations. The company raised approximately $64 million in July 2025, ensuring sufficient funds to support operations into 2028, and expanded its partnership with Almirall to include a second target for dermatological conditions.
Key financial metrics from the second quarter of 2025 show a net loss of $30.6 million, an increase from the $24.8 million loss in the same period last year, primarily due to increased research and development expenses. Revenue decreased to $0.6 million from $1.3 million in the previous year. Despite these losses, Absci’s cash position was bolstered by recent fundraising activities.
Strategically, Absci is advancing its internal pipeline with promising developments such as ABS-101 and ABS-201, which are progressing through clinical trials. The company is also making strides in its AI Drug Creation platform through a collaboration with AMD, aiming to enhance its drug discovery capabilities.
Looking ahead, Absci’s management remains optimistic about the company’s trajectory, focusing on advancing its internal programs and partnerships to drive innovation in drug discovery and development.